FindTrial
Sign In

A randomized, placebo-controlled study investigating the effects of moxaverine on ocular blood flow after oral administration in healthy subjects - MOXOPH3

A randomized, placebo-controlled study investigating the effects of moxaverine on ocular blood flow after oral administration in healthy subjects - MOXOPH3

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-017789-22-AT
Enrollment
Unknown
Registered
2010-04-08
Start date
2010-05-19
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects MedDRA version: 12.1 Level: LLT Classification code 10038881 Term: Retinal microcirculation disorder MedDRA version: 12.1 Level: HLT Classification code 10030067 Term: Ocular vascular disorders NEC

Interventions

Trade Name: Kollateral forte Pharmaceutical Form: Coated tablet INN or Proposed INN: MOXAVERINE HYDROCHLORIDE CAS Number: 1163377 Concentration unit: mg milligram(s) Concentration type: equal Concentr

Sponsors

Ursapharm Arzneimittel GmbH
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Men and women aged between 18 and 35 years, nonsmokers Body mass index between 16 and 30 kg/m² Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant Normal ophthalmic findings, ametropia =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Regular use of medication, abuse of alcoholic beverages or drugs Participation in a clinical trial in the 3 weeks preceding the study Treatment in the previous 3 weeks with any drug Symptoms of a clinically relevant illness in the 3 weeks before the first study day History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of the study drug Blood donation during the previous 3 weeks Presence of any ocular pathology that interferes with the aims of the present study Hypersensitivity to moxaverine Acute gastric bleeding, massive cerebral hemorrhage related to stroke Women: pregnancy or lactation

Design outcomes

Primary

MeasureTime frame
Main Objective: To investigate the effect of orally administrated moxaverine on ocular blood flow in young healthy subjects;Secondary Objective: none;Primary end point(s): Choroidal and optic nerve head blood flow (Laser Doppler Flowmetry)—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026